Why the Troponin Cutoff Is Different for Women and Why It Matters

The number that decides whether a woman’s chest pain is taken seriously as a heart attack was, for decades, calibrated to a man’s body. High-sensitivity troponin assays have sex-specific 99th-percentile thresholds because women’s baseline troponin concentrations are lower than men’s. When a single, higher, male-derived cutoff is applied to both sexes, women with real myocardial injury can register below the threshold and be discharged with a result documented as normal. This is not a theoretical concern. It has been randomized, documented, and quantified in peer-reviewed literature, and the clinical standard has formally moved to recommend sex-specific thresholds. Whether the hospital discharging a given woman has implemented that standard is a different question.

The Mechanism

Troponin is a structural protein complex that anchors actin to myosin in the cardiac sarcomere. It exists in three isoforms: troponin T (cTnT), troponin I (cTnI), and troponin C. The cardiac-specific forms of T and I are released into the bloodstream when cardiomyocytes are damaged or dying. High-sensitivity assays can detect these proteins at concentrations in the nanogram-per-liter range, meaning they are sensitive enough to identify small infarcts, demand ischemia, and myocardial injury from causes other than plaque rupture that older generation assays routinely missed.

The diagnostic threshold is defined as the 99th percentile of a healthy reference population: any troponin concentration above that value is considered abnormal. This statistical approach is appropriate in principle. The problem is that the reference population used to establish the threshold determines what the 99th percentile actually is, and if that reference population is predominantly male, the threshold will be calibrated to male physiology.

Women have lower baseline high-sensitivity troponin concentrations than men in every large reference population studied. The most extensively validated explanation is cardiac muscle mass: women have smaller hearts on average, even after adjustment for body size, meaning a smaller pool of troponin protein is available for release at baseline and during an ischemic event. Sex hormone effects on troponin regulation may also contribute, though this mechanism is less well characterized than the mass differential.

The mathematical consequence is direct: the 99th percentile for a healthy female cohort is numerically lower than the 99th percentile for a healthy male cohort. If a laboratory applies a single combined threshold drawn from a mixed or predominantly male reference distribution, that threshold is set at a value higher than the actual 99th percentile for women. A woman with myocardial injury producing a troponin elevation that exceeds her sex-specific threshold but falls below the male-derived combined threshold will be reported as normal. The injury is real; the reporting system does not detect it.

What the Evidence Shows

The landmark clinical evidence comes from a 2015 randomized controlled study by Shah and colleagues, published in the BMJ. The study enrolled women presenting to the emergency department with symptoms consistent with acute coronary syndrome and randomly assigned them to evaluation using either sex-specific troponin thresholds or the standard sex-neutral threshold. The sex-specific threshold for the assay in use was lower than the standard threshold, reflecting the lower 99th percentile for women.

Using the sex-specific cutoff identified approximately twice as many women with MI compared with the standard threshold. Critically, the additional diagnoses were not false positives: the women identified only by the lower, sex-specific threshold showed evidence of myocardial injury on serial testing and had worse outcomes at follow-up when the MI was not recognized. A woman sent home with a “normal” troponin under the standard threshold had, in a meaningful proportion of cases, actually had a myocardial infarction.

The Shah study is notable not only for what it found but for how it was designed. A randomized comparison of threshold strategies is the appropriate methodological test of whether the threshold choice matters clinically. It does, and the effect size is not marginal.

Subsequent work by Mills and colleagues, published in the Journal of the American College of Cardiology in 2018, analyzed high-sensitivity troponin I concentrations across a large reference population and found sex-specific 99th-percentile values of approximately 16 ng/L for women and 34 ng/L for men on the Abbott Architect assay, a difference of more than twofold. Similar sex-specific differences have been documented across other high-sensitivity assays in widespread clinical use, including the Roche Elecsys hs-cTnT assay and the Siemens ADVIA Centaur assay. The magnitude of the difference varies by assay, but the direction is consistent: women’s 99th percentile is lower.

The Fourth Universal Definition of Myocardial Infarction, the international consensus document published in the European Heart Journal in 2018 by Thygesen and colleagues, formally incorporates sex-specific 99th-percentile upper reference limits as the recommended diagnostic standard for high-sensitivity troponin assays. This is not an emerging suggestion; it is the governing diagnostic framework. The ESC guidelines for management of acute coronary syndromes incorporate the same recommendation.

Adoption in clinical practice has been uneven. A survey of hospital laboratories in the United Kingdom published in Heart in 2020 found that despite guideline recommendations, a substantial proportion of laboratories continued to use a single, sex-neutral threshold because their laboratory information systems had not been updated to support dual reporting or because clinical staff had not been trained in the distinction. Similar implementation gaps have been documented in the United States. The gap between what the evidence recommends and what the laboratory report actually shows is a structural problem, not a scientific uncertainty.

The downstream consequences of that gap are not symmetric. Men with MI who generate troponin elevations above the male-derived threshold are identified correctly. Women who generate elevations below the male threshold but above their sex-specific threshold are falsely reassured and discharged with an unrecognized MI. The standard-of-care failure falls almost entirely on women.

There is also an important point about the serial troponin measurement strategy that emergency departments use. Modern high-sensitivity assay protocols often rely on the combination of an initial value and a delta, the change between measurements at 0 and 1 to 3 hours, to rule MI in or out rapidly. If the initial value is reported against the wrong threshold and considered normal, the clinical team may not interpret a subsequent rise appropriately, because the baseline comparator has already been framed as within-normal. Getting the threshold right at the first measurement is therefore important not only for that result in isolation but for the integrity of the entire serial testing strategy.

Sex-Specific Values Across Common Assays

The sex-specific thresholds are not a single universal number; they vary by assay and need to be looked up for the specific test the laboratory runs. For the Roche Elecsys hs-cTnT assay, the female-specific 99th-percentile upper reference limit is 9 ng/L compared with 19 ng/L for men, a twofold difference, based on the reference population data published by the manufacturer and confirmed in independent cohort analyses. For the Abbott Architect hs-cTnI assay, the values documented by Mills and colleagues in their 2018 JACC analysis were approximately 16 ng/L for women and 34 ng/L for men. The Siemens ADVIA Centaur hs-cTnI assay shows similar sex-stratified differences, with the female-specific threshold running substantially below the male threshold and below any sex-neutral combined value.

These numbers matter because a laboratory applying the sex-neutral combined threshold for the Roche assay would typically use the male value of 19 ng/L as the cutoff for everyone. A woman with a troponin of 12 ng/L would be reported as normal. If that laboratory instead applied the female-specific threshold of 9 ng/L, her result would be flagged as elevated, warranting serial testing and further evaluation. The clinical difference between those two responses is the difference between an identified and an unidentified myocardial infarction at that encounter.

The ESC 0-hour and 1-hour rapid rule-out and rule-in algorithm for suspected MI, updated in the 2020 ESC guidelines for the management of non-ST-elevation acute coronary syndromes, specifies sex-specific thresholds as part of the algorithm. The algorithm is designed to stratify patients rapidly using initial and 1-hour values, and the sex-specific cutoffs are embedded in the recommended decision points. Implementations of this algorithm that do not apply sex-specific thresholds are not implementing the algorithm as specified by the guideline.

The Broader Context of Sex Bias in Cardiac Diagnostics

Troponin threshold calibration is one instance of a broader pattern in cardiac diagnostic development. Standard exercise stress testing, the treadmill ECG, was developed and validated in predominantly male populations and is known to perform less well in women, with lower sensitivity and lower specificity for obstructive CAD than in men. Stress echocardiography protocols were similarly optimized for the obstructive disease patterns more common in men. Coronary CT angiography performs well across sexes, but the disease patterns it detects, dense calcified plaque in large vessels, are less representative of women’s coronary disease, which more often involves diffuse atherosclerosis, non-calcified plaque, and microvascular abnormalities.

This diagnostic architecture, built on populations that did not include enough women to detect sex-specific differences, has created a testing framework that is systematically less sensitive for the patterns of disease women actually have. Troponin thresholds are correctable through laboratory configuration, and that correction is uniquely well-supported by randomized evidence. The Shah BMJ trial is one of the few randomized tests of a diagnostic threshold change, and the evidence it produced can be implemented at the level of a single laboratory updating its reference range.

Peak Troponin Magnitude in Women: Why Smaller Numbers Don’t Mean Smaller Injury

Women with comparable myocardial infarction territory to men generate lower absolute peak troponin concentrations in the blood. This is a separate observation from the threshold calibration problem: it applies not only to the diagnostic cutoff but to the clinical interpretation of any troponin value, including values that have been correctly compared against a sex-specific threshold.

The primary mechanism is cardiac muscle mass. Women have smaller hearts, smaller total cardiomyocyte volume, and a proportionally smaller total troponin protein pool available for release into the circulation during ischemic injury. An infarct that destroys a comparable percentage of myocardial mass will produce lower absolute blood concentrations of troponin in a woman than in a man of larger cardiac size, because the total pool it draws from is smaller.

This creates a compounding problem for clinical care. After the threshold comparison problem is solved and a woman’s troponin is correctly identified as elevated, the magnitude interpretation problem remains. A physician who correctly applies a sex-specific threshold and identifies a troponin of 12 ng/L in a woman as elevated may then interpret that level as a “small” elevation and calibrate the urgency of response accordingly. If the same proportional myocardial injury in a man would produce a troponin of 22 ng/L, the clinical team seeing the man’s result would be more aggressive about invasive evaluation. The woman’s result is correctly flagged but then systematically underinterpreted in severity.

The MINOCA literature documents this pattern directly. Women presenting with myocardial infarction and non-obstructive coronary arteries often have modestly elevated troponin values by absolute number. This absolute modesty leads clinicians to occasionally frame the event as a minor injury rather than a myocardial infarction of clinical significance. The downstream consequence is that these women receive less intensive secondary prevention, less guideline-directed medical therapy, and less aggressive cardiovascular follow-up than men whose troponin values at the same physiological injury level appeared more dramatic on the laboratory report.

Eggers and colleagues published data in the European Heart Journal in 2016 specifically examining sex differences in troponin peak values in confirmed MI, finding that women generated substantially lower peak values at comparable clinical severity, and that this magnitude difference contributed to sex-based disparities in downstream treatment intensity beyond the threshold problem alone. The clinical framework required for accurate interpretation is to treat a woman’s troponin elevation not as intrinsically smaller than a man’s equivalent elevation, but as representing equivalent or greater relative myocardial injury within a smaller absolute pool. The number is smaller. The injury proportionally may not be. 4 / Promising

What to Do This Week

1. If you present to an emergency department with chest pain, pressure, jaw discomfort, unexplained shortness of breath, or other symptoms that could be cardiac, ask two specific questions: which troponin assay is being used, and whether the laboratory applies sex-specific reference ranges for that assay. These are answerable questions that any nurse or physician ordering the test should be able to address.

2. If you are told your troponin is normal and are being discharged, ask whether the result would remain below the threshold using the female-specific 99th-percentile cutoff for that assay. If the clinician does not know the sex-specific value, that is useful information about whether the right comparison was made.

3. If you have a primary care physician, ask whether they know which troponin assay your local hospital uses and whether sex-specific thresholds are applied in that institution’s laboratory. This is the kind of system-level question that a proactive primary care relationship can address before you need it urgently.

4. If you were previously evaluated in an emergency department for chest pain, had a troponin reported as normal, and were discharged without a cardiac diagnosis, it may be worth asking your primary care physician or cardiologist whether that result was compared against a sex-specific threshold. This is particularly relevant if the evaluation occurred before 2019, when sex-specific thresholds were less widely implemented, or at an institution you know to have older laboratory systems.

5. Document the troponin assay name (not just the result) if you are ever tested. Different assays, Elecsys hs-cTnT, Abbott Architect hs-cTnI, Siemens Atellica hs-cTnI, have different sex-specific reference values. The assay name is the piece of information that allows any subsequent clinician to apply the correct threshold to a prior result.

The calibration of a diagnostic threshold is not an abstract methodological issue. It is a mechanism by which myocardial infarctions in women are missed before any clinical judgment is made, before a physician has seen the patient, before a decision about observation or discharge has been considered. The fix is known, formally recommended, and technically available. The question of whether it is implemented at the institution where a given woman presents on a given night is one she has a right to ask.